

DETAILS OF QUARTERLY INVESTOR CALL

Investor call at 9.00am AEST, Wednesday 5th August 2020 to discuss Results and Business Outlook

Adelaide, Australia, 4 August 2020: Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in medical technology automation using artificial intelligence, announces that the Company will hold an investor conference call at **9.00am AEST on Wednesday 5 August 2020** to discuss the Company's activities and financial results for the Quarter ended 30 June 2020 and the business outlook. The Company's CEO and Managing Director, Brent Barnes, will host the call.

How to Access the Investor Call

All attendees must register beforehand to attend the call. After registering, you will receive a confirmation email about joining the webinar including options to attend via computer or telephone.

Please register using the following link:

https://zoom.us/webinar/register/WN_3QVMMowXQfaLBvkG55xCcw

A Q&A session will be held at the end of the conference call, in order to participate in this, you will need to join the conference via computer.

Accessing the Call after the event

A recording of the call will be available on the Investor Centre section of the Company's website for 60 days after the call.

Approved for release by the Chair of the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of the culture plate streaking process. The Company's second product, the Automated Plate Assessment System (APAS®) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beetling's- und Verwaltungs-GmbH. The APAS® instrument is based upon LBT's intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation.

Contacts

LBT Innovations	Investor Enquiries
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com	David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: dallen@hawkesburypartners.com